← Leaderboards
Michael P. Vitek
Regennova, Inc.
$1,349,225
Attributed
$1,349,225
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $500K · FY2022–25$500K$375K$250K$125K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$1,349,225 · 3
By mechanism
R41$999,900 · 2
R44$349,325 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Alzheimer&Apos”
- Kjetil Bjornevik · Harvard University D/B/A Harvard School Of Public Health$3,280,861
- Yanling Wang · Rush University Medical Center$2,986,919
- William G Mantyh · University Of Minnesota$2,961,521
- Allison Mercedes Caban-Holt · University Of Miami School Of Medicine$2,611,182
- Brian Stephen Appleby · Cleveland Clinic Lerner Com-Cwru$2,482,260
- Noah Ray Johnson · University Of Colorado Denver$2,282,487
Research focus
Alzheimer&AposDosePathologyReportingEncephalitisGrowthInflammationCharacteristicsCytokineClinical TrialsDesignEfficacy TestingBloodAnimalsApolipoprotein EAnti-Inflammatory AgentsAffectArginineAmyloidBrain PathologyAmyloid Beta-ProteinClinically RelevantAmericanBrain
Grant awards (3)
Arginine-Polyamine Pathway Inhibitor for Treatment of ADPKD$349,325
R44 · FY2025 · DK · contact PI
A Therapeutic Role for Apolipoprotein-E in the Germ Theory of Alzheimer's Dementia$500,000
R41 · FY2023 · AG · contact PI
Therapeutic Reduction of Cerebral Amyloid Angiopathy Pathologies in ADRD$499,900
R41 · FY2022 · NS · contact PI